Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAAR) is a blank-check company focused on the domestic pharmaceutical manufacturing and life sciences sector. The company filed an 8-K with the Securities and Exchange Commission on July 20, 2026, signaling a material corporate development in its SPAC lifecycle. DMAAR was formed with the stated purpose of identifying and completing a business combination with a target operating in the U.S. drug development or pharmaceutical supply-chain space, reflecting heightened market interest in domestic medicine production. The SPAC remains an active vehicle under SEC review. Sign up at SpacDesk for full filing history, sponsor details, deal status, and real-time alerts on DMAAR and thousands of other SPACs.